An Updated Meta-analysis of Pancreatic Cancer Risk in Patients with Inflammatory Bowel Disease.

IF 1.6 Q4 ONCOLOGY

Journal of Gastrointestinal Cancer Pub Date : 2025-07-02 DOI:10.1007/s12029-025-01266-0

Amir Mohammad Salehi, Shayan Bahadivand Chegini, Sara Danaei, Maryam Hasanzarrini, Fatemeh Shahbazi

{"title":"An Updated Meta-analysis of Pancreatic Cancer Risk in Patients with Inflammatory Bowel Disease.","authors":"Amir Mohammad Salehi, Shayan Bahadivand Chegini, Sara Danaei, Maryam Hasanzarrini, Fatemeh Shahbazi","doi":"10.1007/s12029-025-01266-0","DOIUrl":null,"url":null,"abstract":"Objective: This meta-analysis aims to systematically evaluate the relationship between inflammatory bowel disease (IBD) and the risk of developing pancreatic cancer (PC).Design: Systematic review and meta-analysis.Method: We searched PubMed (Medline), Web of Science, and Scopus up until September 8, 2024. To evaluate heterogeneity among the studies, we used the chi-square test and the I2 statistic. An I2 value exceeding 50% was considered indicative of substantial heterogeneity. We calculated estimates of odds ratios (OR), relative risks (RR), and hazard ratios (HR), along with their corresponding 95% confidence intervals (CI). The analysis was performed using a random-effects model. We established a significance level of less than 0.05 using Stata software, version 17.Results: We included a total of 17 studies in our analysis. Overall, patients with IBD showed a higher risk of developing PC, with an OR = 1.69 (95% CI: 1.48-1.93). Specifically, patients with Crohn's disease (CD) had an OR of 1.25 (95% CI: 1.10-1.41), while those with ulcerative colitis (UC) had an OR = 1.27 (95% CI: 1.10-1.45). Furthermore, patients with IBD accompanied by primary sclerosing cholangitis (PSC) displayed a significantly higher risk, with an OR = 3.12 (95% CI: 1.67-5.85). Additionally, there was no evidence of publication bias across all subgroups. Although there was no publication bias, we conducted a trim-and-fill analysis to investigate the small study effect. This analysis revealed that the results were influenced by omitted studies and that the pooled effects would be diluted if the omitted studies were included in the meta-analysis.Conclusion: CD and UC are associated with an increased risk of PC, with no significant difference in risk levels between the two conditions. However, having IIBD along with PSC increases the risk of PC threefold.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"147"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-025-01266-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This meta-analysis aims to systematically evaluate the relationship between inflammatory bowel disease (IBD) and the risk of developing pancreatic cancer (PC).

Design: Systematic review and meta-analysis.

Method: We searched PubMed (Medline), Web of Science, and Scopus up until September 8, 2024. To evaluate heterogeneity among the studies, we used the chi-square test and the I² statistic. An I² value exceeding 50% was considered indicative of substantial heterogeneity. We calculated estimates of odds ratios (OR), relative risks (RR), and hazard ratios (HR), along with their corresponding 95% confidence intervals (CI). The analysis was performed using a random-effects model. We established a significance level of less than 0.05 using Stata software, version 17.

Results: We included a total of 17 studies in our analysis. Overall, patients with IBD showed a higher risk of developing PC, with an OR = 1.69 (95% CI: 1.48-1.93). Specifically, patients with Crohn's disease (CD) had an OR of 1.25 (95% CI: 1.10-1.41), while those with ulcerative colitis (UC) had an OR = 1.27 (95% CI: 1.10-1.45). Furthermore, patients with IBD accompanied by primary sclerosing cholangitis (PSC) displayed a significantly higher risk, with an OR = 3.12 (95% CI: 1.67-5.85). Additionally, there was no evidence of publication bias across all subgroups. Although there was no publication bias, we conducted a trim-and-fill analysis to investigate the small study effect. This analysis revealed that the results were influenced by omitted studies and that the pooled effects would be diluted if the omitted studies were included in the meta-analysis.

Conclusion: CD and UC are associated with an increased risk of PC, with no significant difference in risk levels between the two conditions. However, having IIBD along with PSC increases the risk of PC threefold.

查看原文本刊更多论文

炎症性肠病患者胰腺癌风险的最新meta分析

目的：本荟萃分析旨在系统评估炎症性肠病（IBD）与发展为胰腺癌（PC）风险之间的关系。设计：系统回顾和荟萃分析。方法：检索PubMed （Medline）、Web of Science和Scopus，检索时间截止到2024年9月8日。为了评估研究之间的异质性，我们使用卡方检验和I2统计量。I2值超过50%被认为表明存在实质性异质性。我们计算了优势比（OR）、相对风险（RR）和风险比（HR）的估计值，以及相应的95%置信区间（CI）。采用随机效应模型进行分析。我们使用Stata软件，版本17建立了小于0.05的显著性水平。结果：我们的分析共纳入了17项研究。总体而言，IBD患者发生PC的风险较高，OR = 1.69 （95% CI: 1.48-1.93）。具体来说，克罗恩病（CD）患者的OR为1.25 (95% CI: 1.10-1.41)，而溃疡性结肠炎（UC）患者的OR = 1.27 （95% CI: 1.10-1.45）。此外，IBD合并原发性硬化性胆管炎（PSC）的患者显示出更高的风险，OR = 3.12 （95% CI: 1.67-5.85）。此外，没有证据表明在所有亚组中存在发表偏倚。虽然没有发表偏倚，但我们进行了一项修正和填充分析来调查小研究的效果。该分析显示，结果受到被省略的研究的影响，如果被省略的研究被纳入meta分析，合并效应将被稀释。结论：CD和UC与PC风险增加相关，两种情况的风险水平无显著差异。然而，IIBD合并PSC会使PC的风险增加三倍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Gastrointestinal Cancer ONCOLOGY-

CiteScore

3.80

自引率

0.00%

发文量

121

期刊介绍： The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.